Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
5(56%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
2
22%
Ph phase_3
1
11%
Ph not_applicable
2
22%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(4)

Detailed Status

Completed4
Recruiting4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 31 (20.0%)
N/A2 (40.0%)

Trials by Status

active_not_recruiting111%
completed444%
recruiting444%

Recent Activity

5 active trials
Showing 5 of 9
active_not_recruitingphase_3

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372
completedphase_1

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

NCT04477512
recruiting

Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters

NCT06716242
recruitingnot_applicable

CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors

NCT06727383
recruiting

Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia

NCT06281262
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03271372Phase 3

Adjuvant Avelumab in Merkel Cell Cancer

Active Not Recruiting
NCT04477512Phase 1

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Completed
NCT06716242

Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters

Recruiting
NCT06727383Not Applicable

CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors

Recruiting
NCT06281262

Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia

Recruiting
NCT04088422

Cell Free DNA in Mature B-cell Lymphoma

Recruiting
NCT03526666

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Completed
NCT03970434Phase 1

Drug Concentration of Metformin According to Sampling Method

Completed
NCT02801942Not Applicable

Immune Profile in Subjects With New Onset Type 1 Diabetes

Completed

All 9 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
9